NEW YORK, July 6 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE
Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical
company with operations in the U.S. and China, today announced that it has
been selected for the award "Best Stem Cell Company, 2010" in The New
Economy's Biotech Awards, which identify excellence in the field of technology.
According to The New Economy's editor Jan Spiegel, who chaired the panel overseeing the awards, "Biotechnology is an exciting field, perhaps nowhere more so than in the area of adult stem cells. The building of NeoStem's adult stem cell platform and its leadership role in this field has been gaining increased recognition including from the Pontifical Council for Culture of the Vatican in the recently announced exclusive collaboration."
Robin Smith, NeoStem's Chairman and CEO, will accept the award at a presentation and interview to be held at the London Stock Exchange on Thursday, July 8, 2010 at 11:00 a.m. GMT. Dr. Smith commented, "We are very pleased to be recognized by The New Economy as an industry leader in stem cells. NeoStem's VSEL(TM) technology represents the cornerstone of our R&D efforts to advance stem cell treatments in two of the world's largest pharmaceutical markets, US and China."
About The New Economy
The New Economy captures the spirit of thought leadership. Both the magazine and the website are committed to the very highest standards of journalism, working together with experts from leading technology think tanks, public and private sector organizations, and academics from the most esteemed educational and research centers around the world, to bring regularly updated news, deep analysis of the issues of the day and clear and precise explanations of emerging technologies.
Winners of The New Economy 2010 Awards have been selected based on criteria such as innovation, originality and quality of product, as well as proof of market development and excellence in client representation.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSELTM Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL TM Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Advertisement
According to The New Economy's editor Jan Spiegel, who chaired the panel overseeing the awards, "Biotechnology is an exciting field, perhaps nowhere more so than in the area of adult stem cells. The building of NeoStem's adult stem cell platform and its leadership role in this field has been gaining increased recognition including from the Pontifical Council for Culture of the Vatican in the recently announced exclusive collaboration."
Advertisement
Robin Smith, NeoStem's Chairman and CEO, will accept the award at a presentation and interview to be held at the London Stock Exchange on Thursday, July 8, 2010 at 11:00 a.m. GMT. Dr. Smith commented, "We are very pleased to be recognized by The New Economy as an industry leader in stem cells. NeoStem's VSEL(TM) technology represents the cornerstone of our R&D efforts to advance stem cell treatments in two of the world's largest pharmaceutical markets, US and China."
About The New Economy
The New Economy captures the spirit of thought leadership. Both the magazine and the website are committed to the very highest standards of journalism, working together with experts from leading technology think tanks, public and private sector organizations, and academics from the most esteemed educational and research centers around the world, to bring regularly updated news, deep analysis of the issues of the day and clear and precise explanations of emerging technologies.
Winners of The New Economy 2010 Awards have been selected based on criteria such as innovation, originality and quality of product, as well as proof of market development and excellence in client representation.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSELTM Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL TM Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact:
NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: [email protected]
Web: http://www.neostem.com
CCG Investor Relations, Inc.
Kalle Ahl, Account Manager
Phone: +1-646-833-3417
Email: [email protected]
Web: http://www.ccgirasia.com
Crocker Coulson, President
Phone: +1-646-213-1915
Email: [email protected]
SOURCE NeoStem, Inc.